Evidence map›Paper›PMID 31228097›Full record

ArticleDrug delivery and translational research2019

Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8

Qiuqiang Chen, Ying Bao, Danielle Burner, Sharmeela Kaushal, Yu Zhang, Theresa Mendoza, Michael Bouvet, Cengiz Ozkan, Boris Minev, Wenxue Ma

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Bolstering CD8Biology · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Current Prospects in Peptide-Based Subunit Nanovaccines.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  12. Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Qiuqiang ChenKey Laboratory for Translational Medicine, The First Affiliated Hospital of Huzhou University School of Medicine, Huzhou, 313000, Zhejiang, China.
Ying BaoKey Laboratory for Translational Medicine, The First Affiliated Hospital of Huzhou University School of Medicine, Huzhou, 313000, Zhejiang, China.
Danielle BurnerDepartment of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Sharmeela KaushalDepartment of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Yu ZhangMaterials Science and Engineering Program, Department of Mechanical Engineering, University of California Riverside, Riverside, CA, 92521, USA.
Theresa MendozaDepartment of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Michael BouvetDepartment of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Cengiz OzkanMaterials Science and Engineering Program, Department of Mechanical Engineering, University of California Riverside, Riverside, CA, 92521, USA.
Boris MinevDepartment of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA. bminev@ucsd.edu.
Wenxue MaDepartment of Clinical Medicine, Huzhou University School of Medicine, Huzhou, 313000, Zhejiang, China. wma@ucsd.edu.ORCID 0000-0001-9228-6162
University of California San Diego · USHuzhou University · CNUniversity of California, Riverside · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poly(lactic-co-glycolic) acid (PLGA) has been successfully used in drug delivery and biomaterial applications, but very little attention has been directed towards the potential in vivo effects of peptide-loaded PLGA nanoparticles (NPs), specifically the potency of intravenous (IV) STEAP peptide-loaded PLGA-NP (nanovaccine) dosing and whether STEAP-specific CD8

Indexed as

AnimalsAntigens, NeoplasmCancer VaccinesCD8-Positive T-LymphocytesCell Line, TumorLiverLungMaleMice, Inbred C57BLNanoparticlesPolylactic Acid-Polyglycolic Acid CopolymerProstatic NeoplasmsAntigens, NeoplasmCancer VaccinesPolylactic Acid-Polyglycolic Acid CopolymerSteap protein, mouseAntigenic peptideAntigen-presenting cellsCancer immunotherapyNanovaccinePoly(lactide-co-glycolide) acid

Identifiers

PMID31228097
OpenAlexW2952318258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.